FUS (Fused in Sarcoma) proteinopathy is a neurodegenerative mechanism characterized by the abnormal accumulation of the FUS protein in the cytoplasm of [neurons](/entities/neurons) and glia. This pathological process is a hallmark of certain forms of amyotrophic lateral sclerosis (ALS) and Frontotemporal Dementia (FTD)[@deng2014]. FUS is a 526-amino acid RNA-binding protein that plays critical roles in RNA metabolism, including transcription, splicing, transport, and translation. Under normal conditions, FUS predominantly localizes to the nucleus, but in FUS proteinopathy, the protein mislocalizes to the cytoplasm where it forms insoluble inclusions[@ling2013]. The discovery of FUS mutations as a cause of familial ALS in 2009 marked a significant breakthrough in understanding ALS pathogenesis. Approximately 5-10% of familial ALS cases and a smaller percentage of FTD cases are associated with FUS mutations[@suzuki2012].
Molecular Biology of FUS
Normal Function
FUS is a member of the FET (FUS, EWS, TAF15) family of RNA-binding proteins characterized by:
N-terminal prion-like domain: Low-complexity regions that facilitate liquid-liquid phase separation
RNA recognition motifs (RRMs): Bind specific RNA sequences
FUS (Fused in Sarcoma) proteinopathy is a neurodegenerative mechanism characterized by the abnormal accumulation of the FUS protein in the cytoplasm of [neurons](/entities/neurons) and glia. This pathological process is a hallmark of certain forms of amyotrophic lateral sclerosis (ALS) and Frontotemporal Dementia (FTD)[@deng2014]. FUS is a 526-amino acid RNA-binding protein that plays critical roles in RNA metabolism, including transcription, splicing, transport, and translation. Under normal conditions, FUS predominantly localizes to the nucleus, but in FUS proteinopathy, the protein mislocalizes to the cytoplasm where it forms insoluble inclusions[@ling2013]. The discovery of FUS mutations as a cause of familial ALS in 2009 marked a significant breakthrough in understanding ALS pathogenesis. Approximately 5-10% of familial ALS cases and a smaller percentage of FTD cases are associated with FUS mutations[@suzuki2012].
Molecular Biology of FUS
Normal Function
FUS is a member of the FET (FUS, EWS, TAF15) family of RNA-binding proteins characterized by:
N-terminal prion-like domain: Low-complexity regions that facilitate liquid-liquid phase separation
RNA recognition motifs (RRMs): Bind specific RNA sequences
Transcriptional regulation through interaction with RNA polymerase II
Alternative splicing regulation
RNA transport and local translation in dendrites
DNA damage response
Formation of stress granules
Pathogenic Mechanisms
1. Mislocalization
Mutations in FUS cause loss of nuclear localization signals (NLS), leading to cytoplasmic accumulation. The most common ALS-associated mutations include:[@kwok2020]
P525L (highly aggressive, juvenile-onset)
R521C (most common, adult-onset)
R522G, R521H
2. Phase Separation Dysregulation
FUS undergoes liquid-liquid phase separation (LLPS) to form stress granules and other RNA-protein complexes. Disease-causing mutations alter the material properties of these condensates, promoting:[@murakami2015]
Increased viscosity
Reduced dynamics
Transition to solid-like aggregates
Sequestration of essential RNA binding proteins
3. RNA Metabolism Dysfunction
FUS proteinopathy disrupts multiple aspects of RNA metabolism:
Aberrant alternative splicing
Impaired RNA transport
Disrupted local translation at synapses
Toxic gain-of-function in stress granules
4. Nucleocytoplasmic Transport Defects
FUS inclusions disrupt nuclear pore integrity and impair nucleocytoplasmic transport, a mechanism shared with [TDP-43](/proteins/tdp-43) Proteinopathy and [C9orf72](/entities/c9orf72)-associated diseases.[@jovicic2015]
Disease Associations
Amyotrophic Lateral Sclerosis (ALS)
FUS-ALS is characterized by:[@kwok2020]
Rapid progression: Faster disease than sporadic ALS
Younger age of onset: Often presents before age 40
Bulbar onset: Higher frequency of bulbar involvement
Cognitive involvement: Some patients develop FTD features
Upper motor neuron predominance: Prominent corticospinal tract involvement
Frontotemporal Dementia (FTD)
FUS-positive inclusions are found in:[@dormann2011]
[Deng H, Gao K, Jankovic J, The role of FUS gene in neurodegenerative disease (2014)](https://doi.org/10.1016/j.neurobiolaging.2013.09.031)
[Ling SC, Polymenidou M, Cleveland DW, Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis (2013)](https://doi.org/10.1016/j.neuron.2013.07.033)
[Suzuki N, Aoki M, FUS mutations in ALS and FTD (2012)](https://pubmed.ncbi.nlm.nih.gov/22277162/)
[Kwok CT, Morris AG, Fratta P, et al, FUS-ALS: Clinical features and genetic heterogeneity (2020)](https://doi.org/10.1136/jnnp-2020-323588)
[Dormann D, Haass C, TDP-43 and FUS: Nuclear protein aggregation (2011)](https://doi.org/10.1038/emboj.2011.134)
[Murakami T, Qamar S, Lin JQ, et al, ALS/FTD Mutation-Induced Phase Transition of FUS (2015)](https://doi.org/10.1016/j.neuron.2015.08.020)
[Jovicic A, Mertens J, Boeynaems S, et al, Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS (2015)](https://doi.org/10.1038/nn.4085)
[Buttner S, Makryiannis A, Herholz M, et al, FUS-mediated nuclear transport in ALS pathogenesis and therapeutic targeting (2020)](https://doi.org/10.1038/s41582-020-0356-0)
[Gasset-Rosa F, Lujas A, Blasco H, et al, Targeting phase separation as a therapeutic strategy in ALS/FTD (2024)](https://doi.org/10.1016/j.tins.2023.11.005)
[Filippini A, Gennari M, Setti A, et al, Clinical phenotypes and genetic spectrum of FUS-ALS: A systematic review (2023)](https://doi.org/10.1007/s00415-022-11501-3)
[Shenoy J, Dhakal D, Berger S, et al, FUS aggregates: From liquid-liquid phase separation to amyloid fibrils (2023)](https://doi.org/10.1007/s00401-023-02608-7)
[Vazquez-Sanchez S, et al., Frontotemporal dementia-like disease progression elicited by seeded aggregation (2024)](https://pubmed.ncbi.nlm.nih.gov/38895337/)
[Lin J, et al., Design principles to tailor Hsp104 therapeutics (2024)](https://pubmed.ncbi.nlm.nih.gov/38712168/)
[Honda H, et al., Increased expression of human antiviral protein MxA in FUS proteinopathy (2024)](https://pubmed.ncbi.nlm.nih.gov/37586842/)